OVARIAN TRANSITIONAL CELL CARCINOMA
Clinical trials for OVARIAN TRANSITIONAL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN TRANSITIONAL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN TRANSITIONAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo battles Tough-to-Treat ovarian cancer
Disease control OngoingThis study is for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned and stopped responding to standard platinum-based chemotherapy. It aims to see if taking two oral drugs, cediranib and olaparib, together works better than taking either drug alone or…
Matched conditions: OVARIAN TRANSITIONAL CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 22:56 UTC
-
Doctors test 'Trojan Horse' stem cells carrying Cancer-Killing virus
Disease control OngoingThis early-phase trial is testing a new treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after standard therapy. Researchers are using a patient's own fat-derived stem cells to carry a specially engineered measles virus directly to the cancer…
Matched conditions: OVARIAN TRANSITIONAL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 03, 2026 22:55 UTC
-
Trial tests weekly vs. standard chemo for Tough-to-Treat cancers
Disease control OngoingThis large study aimed to find out if giving a key chemotherapy drug (paclitaxel) once a week is better than giving it once every three weeks for treating advanced ovarian, fallopian tube, or primary peritoneal cancer. All participants also received another chemotherapy drug (car…
Matched conditions: OVARIAN TRANSITIONAL CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Pill vs. IV drip: major trial tests easier treatment for returning ovarian cancer
Disease control OngoingThis large, late-stage trial is testing whether taking pills (olaparib alone or with cediranib) works as well or better than standard intravenous chemotherapy for women whose ovarian, fallopian tube, or primary peritoneal cancer has returned but still responds to platinum drugs. …
Matched conditions: OVARIAN TRANSITIONAL CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Major trial aims to tame dozens of rare, neglected cancers with immune power combo
Disease control OngoingThis large national trial is testing whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help control over 50 different types of rare cancers that have few or no standard treatment options. It enrolled over 800 adults whose rare cancers had progressed …
Matched conditions: OVARIAN TRANSITIONAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Major trial tests new combo to fight back when ovarian cancer returns
Disease control OngoingThis large, late-stage trial is for people whose ovarian, fallopian tube, or primary peritoneal cancer has returned after initial successful treatment. It aims to find the best way to control the cancer by testing whether adding a drug called bevacizumab to standard chemotherapy,…
Matched conditions: OVARIAN TRANSITIONAL CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC